Consistent with the pathological findings, flow cytometric analysis of xenograft tumors clearly demonstrated that metformin markedly reduced the number of tumor-initiating EpCAM+ cells, whereas sorafenib did not (Fig. 8A). This evidence concerns the gene EPCAM and neoplasm.